Following on from information provided to NICE by the company in January 2020, the appraisal of Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1146 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 January 2020 | The Department for Health and Social Care has asked NICE to carry out an appraisal of avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 17 January 2020 | Suspended. Referred February 13 2018 |
| 25 April 2018 - 24 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 13 February 2018 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual